Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66

Benzinga · 15h ago
Guggenheim analyst Delma Caiati maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and lowers the price target from $70 to $66.